AstraZeneca Archives - Pharmaphorum

Interview: AZ’s immunotherapy gamble starts to pay off

September 22, 2017

Robert Iannone, AstraZeneca’s head of immune-oncology research, on the unpredictable immunotherapy market.

Interview: AZ’s immunotherapy gamble starts to pay off

https://pharmaphorum.com/views-and-analysis/az-immunotherapy-gamble-pays-off/

Novo aims for GLP-1 sales growth in China

September 21, 2017

Novo expects Victoza and semaglutide to gain momentum.

Novo aims for GLP-1 sales growth in China

https://pharmaphorum.com/news/novo/

Tesaro’s Zejula primed for EU approval, battle with AZ

September 18, 2017

EU regulators recommend PARP inhibitor Zejula

Tesaro’s Zejula primed for EU approval, battle with AZ

https://pharmaphorum.com/news/tesaro/

AZ talks up Bydureon data, GLP-1 and glucagon combo

September 14, 2017

AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition

AZ talks up Bydureon data, GLP-1 and glucagon combo

https://pharmaphorum.com/news/az-hopes-bydureon-mortality-benefit-stave-off-threat-novo/

Novo showcases next-gen GLP-1 at EASD

September 13, 2017

Semaglutide is under review in Europe and US.

Novo showcases next-gen GLP-1 at EASD

https://pharmaphorum.com/news/novo-showcases-next-gen-glp-1-easd/

ESMO 2017 round up: BMS and AZ bounce back

September 12, 2017

Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking

ESMO 2017 round up: BMS and AZ bounce back

https://pharmaphorum.com/news/esmo-2017-round-bms-az-bounce-back/

Tagrisso on target to be EGFR+ lung cancer standard

September 9, 2017

New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in

Tagrisso on target to be EGFR+ lung cancer standard

https://pharmaphorum.com/news/tagrisso-target-egfr-lung-cancer-standard/

FDA puts hold on AZ and Celgene immunotherapy trials

September 8, 2017

Regulator is exploring safety of immunotherapy combinations in blood cancer

FDA puts hold on AZ and Celgene immunotherapy trials

https://pharmaphorum.com/news/fda-puts-hold-az-celgene-immunotherapy-trials/

Innovations in cancer drug research

September 4, 2017

While cancer continues to be one of the leading causes of death and illness, new technology and increasing

Innovations in cancer drug research

https://pharmaphorum.com/views-and-analysis/innovations-cancer-drug-research/

Trending

AstraZeneca

Hello World

Interview: AZ’s immunotherapy gamble starts to pay off

Novo aims for GLP-1 sales growth in China

Tesaro’s Zejula primed for EU approval, battle with AZ

AZ talks up Bydureon data, GLP-1 and glucagon combo

Novo showcases next-gen GLP-1 at EASD

ESMO 2017 round up: BMS and AZ bounce back

Tagrisso on target to be EGFR+ lung cancer standard

FDA puts hold on AZ and Celgene immunotherapy trials

Innovations in cancer drug research

CDD for Biologics Summit 2017

Neoantigen Summit 2017

ICI Summit Europe 2017

6th International GMP, GCP & Quality Control Summit

Inhalation and Respiratory Drug Products Summit

3rd Annual Pre-Filled Syringes Summit

Search

Advanced Search

Trending

AstraZeneca

Hello World